SciY launches new BioDrive tool and registration module for enhanced data management and collaboration in molecular biology research

The liver APOC3-targeted RNA interference agent plozasiran proved its triglyceride-lowering effects in people with mixed hyperlipidemia in the phase IIb MUIR trial. In such individuals,

AC Im­mune’s an­ti-pTau drug en­ters PhI­Ib: The Swiss biotech’s part­ner John­son & John­son launched the “po­ten­tial­ly reg­is­tra­tion-en­abling” study of ACI-35.030 in peo­ple with pre­clin­i­cal Alzheimer’s